Journal article icon

Journal article

Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy

Abstract:

Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcriptional suppression of PD-L1 expression as an alternative therapeutic anti-melanoma strategy has not been exploited. Here we provide biochemical evidence demonstrating that ultraviolet radiation (U...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41388-018-0314-0

Authors


More from this funder
Name:
Priority Academic Program Development of Jiangsu Higher Education Institutions
Grant:
IntegrationofChinese
WesternMedicinegrant(PC
More from this funder
Name:
National Natural Science Foundation of China
Grant:
81673977 for 2016 for XM
More from this funder
Name:
Melanoma Research Foundation
Grant:
Establish Investigator Award (RC
More from this funder
Name:
National Institutes of Health
Grant:
R01CA137098,R01CA193913
R01CA196896
Publisher:
Springer Nature
Journal:
Oncogene More from this journal
Volume:
37
Pages:
4941–4954
Publication date:
2018-05-22
Acceptance date:
2018-04-20
DOI:
EISSN:
1476-5594
ISSN:
0950-9232
Keywords:
Pubs id:
pubs:846503
UUID:
uuid:d0985f16-1fd8-4bd3-8a63-26e8b0d45bee
Local pid:
pubs:846503
Source identifiers:
846503
Deposit date:
2018-05-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP